monoclonal antibody

AbbVie and FutureGen Partner on Inflammatory Bowel Disease Treatment

US drugmaker AbbVie and Chinese biopharmaceutical company FutureGen have entered into a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of inflammatory bowel disease (IBD) currently in preclinical testing.

Evolution of Technology

Opportunities in Drug Development and Manufacturing

Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.

FDA Accepts Valeant-AstraZeneca Psoriasis Application

Merck-Pfizer Alliance Joins Syndax on Ovarian Cancer

Merck-Pfizer Avelumab on FDA Fast Track

Significant Value Creation

The Biosimilar Market

Cerbios' New Manufacturing Plant Enters Qualification Phase